FDA Panel Recommends Centocor’s Ustekinumab Approval; Questions Dosing
Executive Summary
Centocor should conduct additional studies of ustekinumab to evaluate potential interim doses, according to FDA's Dermatologic and Ophthalmic Drugs Advisory Committee
You may also be interested in...
FDA To Centocor: Show Me The REMS For Ustekinumab
After an earlier three-month delay of its ustekinumab user fee date, Centocor is facing yet another setback in getting FDA approval for the potentially first-in-class monoclonal antibody to treat chronic moderate to severe plaque psoriasis in adults
FDA To Centocor: Show Me The REMS For Ustekinumab
After an earlier three-month delay of its ustekinumab user fee date, Centocor is facing yet another setback in getting FDA approval for the potentially first-in-class monoclonal antibody to treat chronic moderate to severe plaque psoriasis in adults
FDA To Centocor: Show Me The REMS
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.